Unveiling a Universal Approach to Gene Editing

At a recent WIRED Health summit, David Liu, a trailblazer in gene editing, hinted at his laboratory's groundbreaking plans to introduce a single gene-editing method capable of addressing a variety of diseases unrelated by genetic mutations. He refers to this as therapeutic gene editing that transcends specific diseases.

While it might seem far-fetched at first, Liu assured the attendees in Boston that there is substantial molecular biology rationale supporting this possibility. However, he refrained from divulging further specifics.

Current developments in gene-editing treatments focus on rare genetic conditions. Notable among these is a method approved for addressing sickle cell anemia and the similar blood disorder beta thalassemia. Additionally, this year marked a historic moment when an infant named KJ Muldoon, born with a critical genetic defect leading to ammonia accumulation in his bloodstream, was saved through gene editing.

The effectiveness of these therapies lies in their ability to correct specific genetic mutations. However, creating such therapies is costly and tailored for particular demographic groups, sometimes as small as KJ's case. His condition, CPS1 deficiency, is extraordinarily rare, occurring in roughly one out of 1.3 million births.

Liu envisions a future where a universal gene-editing protocol could be utilized across multiple diseases, irrespective of the tissues or organs impacted or their genetic origins. Considering the vast array of rare diseases—Global Genes estimates over 10,000 affecting more than 400 million individuals—such a universal strategy is necessary.

Liu noted that genetic diseases are more frequent than commonly acknowledged—exceeding even cancer or HIV/AIDS in prevalence. He emphasized the urgency of developing methods to target the genetic roots of these disorders effectively.

Liu's lab has pioneered advanced techniques such as base editing and prime editing to tackle rare diseases. These innovations are currently undergoing rigorous clinical evaluation in various global trials.

Base editing employs engineered proteins to modify a single DNA base, swapping one 'letter' in the DNA code for another, much like correcting a typo. This method was pivotal in treating baby KJ.

Conversely, prime editing offers a cutting-edge 'search-and-replace' mechanism. Traditional methods break the DNA strands, whereas prime editing refines sequence alterations more gently, enabling targeted edits like additions, deletions, or replacements without breaking the DNA strands. This method acts like a sophisticated DNA editing tool.

At the summit, Liu offered insight into leveraging prime editing universally across various diseases. He suggested that this capability could pave the way for developing a single therapeutic agent benefitting a larger number of patients, uplifting the reach and effectiveness of gene-editing technologies.

In envisioning this future, Liu believes gene editing's transformative potential can be magnified. Most importantly, it would broaden patient access to crucial treatments previously undeliverable on such a scale.